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Abstract Hag¢sh intestinal antimicrobial peptides (HFIAPs)
are a family of polycationic peptides exhibiting potent, broad-
spectrum bactericidal activity. In an attempt to unravel the
mechanism of action of HFIAPs, we have studied their inter-
action with model membranes. Synthetic HFIAPs selectively
bound to liposomes mimicking bacterial membranes, and caused
the release of vesicle-encapsulated £uorescent markers in a size-
dependent manner. In planar lipid bilayer membranes, HFIAPs
induced erratic current £uctuations and reduced membrane line
tension according to a general theory for lipidic pores, suggest-
ing that HFIAP pores contain lipid molecules. Consistent with
this notion, lipid transbilayer redistribution accompanied
HFIAP pore formation, and membrane monolayer curvature
regulated HFIAP pore formation. Based on these studies, we
propose that HFIAPs kill target cells, at least in part, by in-
teracting with their plasma membrane to induce formation of
lipid-containing pores. Such a membrane-permeabilizing func-
tion appears to be an evolutionarily conserved host-defense
mechanism of antimicrobial peptides.
( 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Over the last 25 years, research has established that anti-
microbial peptides are important components of the innate
immune system in animals, playing a role in the ¢rst line of
defense against invading microbes [1]. Although varying in
length and primary structure, most antimicrobial peptides
are polycationic at physiological pH, and adopt amphipathic
secondary structures in which the cationic and hydrophobic
residues segregate on opposite surfaces of K-helical or L-sheet
motifs [2]. Such features enable these peptides to interact with
the plasma membrane of target organisms and to breach this
permeability barrier. Studies with synthetic peptide analogues
and model lipid membranes have provided valuable insight
into the mechanism(s) underlying membrane permeabilization
by antimicrobial peptides. Several models have been proposed
which can be classi¢ed in two general groups: formation of
purely peptidic channels, and formation of lipid^peptide com-
posite pores [1^4].
Hag¢sh intestinal antimicrobial peptides (HFIAPs) consti-
tute an intriguing group of bioactive peptides. Isolated from a
primitive ¢sh lacking components of the vertebrate adaptive
immune system, such as thymus tissue and immunoglobulin
genes [5], HFIAPs are implicated as important components of
the hag¢sh innate immune system [6]. Synthetic HFIAPs ex-
hibit potent, broad-spectrum antibacterial activity but low
activity against the prototypic fungus, C. albicans [6]. Their
biosynthesis is localized in nests of hematopoietic cells within
the intestinal submucosa, rather than in the epithelial lining of
the hag¢sh gut, yet HFIAPs do not display signi¢cant hemo-
lytic activity in vitro. Although native HFIAPs contain one or
two residues of mono-brominated tryptophan, this unusual
amino acid is not critical for conferring antimicrobial function
(A.E. Shinnar et al., unpublished). Recent cDNA analysis of
HFIAP clones shows that they are ancient ancestors of the
cathelicidin gene family, for which members have been iden-
ti¢ed in various mammals, suggesting that their biological
function has been evolutionarily conserved (T. Uzzell et al.,
unpublished).
In this work, the e¡ect of HFIAPs on model lipid mem-
brane systems has been investigated in order to elucidate their
bactericidal mechanism of action. We show that HFIAPs bind
to and induce permeabilization of vesicles mimicking mem-
branes surface lipid compositions of bacteria but not of eryth-
rocytes or C. albicans. We also present several lines of evi-
dence supporting a model whereby, similar to magainin and
analogous antimicrobial peptides, HFIAPs permeabilize mem-
branes by forming pores containing bent lipid molecules.
2. Materials and methods
2.1. Materials
Dioleoylphosphatidylcholine (PC), dioleoylphosphatidylethanol-
amine (PE), dioleoylphosphatidylglycerol (PG), dioleoylglycerol
(DG), oleoylphosphatidycholine (LPC), oleoylphosphatidylethanol-
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PE, dioleoylphosphatidylethanolamine; PG, dioleoylphosphatidylgly-
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amine (LPE), sphingomyelin (SM) and cholesterol (CHOL) were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA). KCl,
HEPES, EDTA, decane, Triton X-100, oleic acid (OA) and £uores-
cein isothiocyanate-labeled dextrans ofV4 kDa (FD-4) orV70 kDa
(FD-70) were from Sigma (St. Louis, MO, USA). 8-aminonaphtalene-
1,3,6 trisulfonate (ANTS) and p-xylene-bis-pyridinium bromide
(DPX) were from Molecular Probes (Eugene, OR, USA). 1-lauroyl-
2-(1Ppyrenebutyroyl)-sn-glycero-3-phosphocholine (Pyr-PC) was a
kind gift of Dr. Andreas Herrman (Humboldt University, Berlin,
Germany).
2.2. Synthetic peptides
Synthetic HFIAPs, prepared with native tryptophan, were provided
by Genaera Corporation Sequences, corresponding to the C-termi-
nally amidated peptides were: HFIAP-1 GFFKKAWRKVKHAGR-
RVLDTAKGVGRHYVNNWLNRYR; HFIAP-3 GWFKKAWRK-
VKNAGRRVLKGVGIHYGVGLI.
2.3. Liposome preparation and assays
Large unilamellar vesicles (LUV) were prepared by the freeze/thaw
and extrusion method as described before [7]. Dry lipid ¢lms were
resuspended in the following bu¡ers: (i) membrane-binding assays:
100 mM KCl, 10 mM HEPES, pH 7.0, 0.2 mM EDTA (KHE), using
D2O instead of H2O; (ii) release of vesicle contents: 12.5 mM ANTS,
45 mM DPX, 20 mM KCl, 10 mM HEPES, pH 7.0, 0.2 mM EDTA
or KHE supplemented with 100 mg/ml FD; (iii) lipid £ip-£op: KHE.
For measuring HFIAP binding to LUV, peptides and vesicles were
incubated together at 37‡C for 30 min in D2O bu¡er, and then the
mixture was centrifuged at 200 000Ug at room temperature for 2 h.
Under these conditions, vesicle-bound HFIAP remains with the upper
fraction of the bu¡er, whereas free peptide sediments [8]. Peptide
contents of LUV-associated or LUV-free fractions were estimated
on the basis of the £uorescence intensities at Vex = 280 nm and
Vem = 345 nm, after addition of 0.5 mM C12E18 (dodecyl octaethyle-
neglycol mono ether). Fluorimetric assays were conducted in an 8100
SIM-Aminco instrument, using a thermostatted 1-cm path length cuv-
ette with constant stirring at 37‡C. Assays of vesicular release of £uo-
rescent markers were performed as described in [7]. Experiments of
pyPC transbilayer redistribution were done according to the method
of Muller et al. [9].
2.4. Planar lipid bilayer membrane assays
Measurements were performed in decane-containing lipid bilayer
membranes composed of egg phosphatidylethanolamine/egg phospha-
tidylglycerol (1:1), formed by the Mueller^Rudin technique across a
250-Wm hole in a Lucite chamber (Warner, Hamden, CO, USA). KHE
was used as the bathing solution. Membrane lifetime and line tension
values were calculated as described in [10].
3. Results and discussion
3.1. Membrane-binding properties of HFIAP
HFIAPs are much more potent in inducing cell death of
bacterial cells than of fungi or red blood cells [6]. The ¢rst
step in the interaction of HFIAPs with any cell is the transfer
of peptides from the extracellular environment to the cell sur-
face. In order to mimic the primary lipid composition of the
plasma membrane surfaces of bacteria [11], erythrocytes [12]
and C. albicans [13], LUV composed of PE/PG (molar ratio
1:1), PC/CHOL/SM (1:1:1), and PC/CHOL (1:1) were used,
respectively. HFIAPs associated with bacterial membrane
mimetic LUV to a much greater extent than to erythrocyte
or C. albicans membrane mimetic LUV (Fig. 1A). A distin-
guishing feature between the membranes of prokaryotic and
eukaryotic organisms is that the former but not the latter
contain negatively charged lipids in the outer lea£et of the
cytoplasmic membrane [14]. To investigate whether electro-
static interactions are an important factor determining the
membrane-binding capacity of HFIAPs, LUV containing var-
ious proportions of PC and PG were used. As shown in Table
1, the higher the proportion of PG in the liposomal mem-
brane, the larger the amount of HFIAP-1 and HFIAP-3
bound to LUV. The extent of peptide binding is in line with
their polycationic character, with HFIAP-1 and HFIAP-3 dis-
playing a net charge of +12 and +9, respectively, at neutral
pH. Thus, the selective cell-killing activity of HFIAPs against
Fig. 1. E¡ect of HFIAPs in LUV emulating the outer lea£et lipid
matrix of bacterial, erythrocyte, and C. albicans plasma membranes.
A: Binding of HFIAP to LUV mimicking membranes of bacteria
(PE/PG, molar ratio 1:1), erythrocytes (PC/SPM/CHOL, 1:1:1),
and C. albicans (PC/CHOL, 1:1). Black bars, HFIAP-1; white bars,
HFIAP-3. Lipid and peptide concentrations were 200 WM and 1 WM,
respectively. Values represent mean valuesS S.E.M. of duplicate ex-
periments. B: Representative kinetics of HFIAP-1-induced ANTS
release from PE/PG (1:1), PC/SM/CHOL (1:1:1), and PC/CHOL
(1:1) LUV. Peptide and lipid concentrations were 1 WM and 25
WM, respectively. Similar results were obtained with HFIAP-3.
C: Extents of ANTS release induced by HFIAP-1 (black symbols)
and HFIAP-3 (white symbols) in LUV of PE/PG (1:1) (circles), PC/
SM/CHOL (1:1:1) (squares) and PC/CHOL (triangles) at various
peptide-to-lipid molar ratios. Concentration of lipid was 25 WM.
Mean valuesS S.E.M. values correspond to three to seven separate
experiments.
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Table 1
Comparison of the capacity of HFIAPs to bind to and permeabilize LUV of di¡erent lipid compositions
Lipid composition HFIAP-1 HFIAP-3
% bounda % releaseb % bound % release
ANTS FD-4 FD-70 ANTS FD-4 FD-70
PC 4S1 5S 0 4S0 0 9S 2 2S 1 0 N.D.
PC/PG (3/1) 29S 3 33S 5 26S4 0 36S 6 28S 4 10S1 0
PC/PG (1/1) 68S 8 74S 6 76S8 8S 1 83S 7 69S 6 36S2 0
PC/PG (1/3) 84S 7 85S 8 78S6 17S 3 79S 7 91S 7 70S9 0
PG 82S 9 93S 7 84S9 25S 3 85S 9 89S 6 74S7 6S 1
PE/PG (1/1) 80S 11 62S 5 50S4 14S 2 86S 8 44S 4 13S0 N.D.
PC/CHOL (1/1) 5S 2 3S 0 1S0 1S 0 4S 1 3S 0 0 N.D.
PC/CHOL/SM (1/1/1) 4S 1 4S 0 6S1 N.D. 11S 3 3S 1 2S0 N.D.
Mean valuesS S.E.M. shown for two to six independent experiments. N.D., not determined.
aPeptide and lipid concentrations were 1 WM and 200 WM, respectively.
bPeptide and lipid concentrations were 0.5 WM and 25 WM, respectively.
Fig. 2. E¡ect of HFIAPs in planar lipid bilayer membranes. A: Typical electrical activities observed after addition HFIAP-1 to a solution bath-
ing a planar bilayer membrane. Note the di¡erent scales of the two current traces. The voltage in the top and bottom recordings was 50 mV
and 130 mV, respectively. Peptide concentration was 300 nM in both cases. Lower peptide concentrations led to similar but delayed electrical
responses. B: Dose-dependent decrease of membrane lifetime induced by HFIAP-1 (black circles) and HFIAP-3 (white circles). Voltage was
300 mV. All points are mean values SS.E.M. (n=8^12). C: Dose-dependent reduction of membrane line tension induced by HFIAP-1 (black
circles) and HFIAP-3 (white circles).
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bacteria is likely exerted at the level of electrostatic binding to
the anionic membrane surface of these microorganisms.
3.2. LUV-permeabilizing properties of HFIAP
Once HFIAPs have reached the membrane surface, they
may perturb the lipid bilayer permeability barrier, as other
antimicrobial peptides apparently do [1^4]. To address this
issue, LUV were loaded with the £uorescent marker ANTS
and its quencher, DPX, and the release of ANTS from LUV
was monitored as an increase in the £uorescence of the dye
due to its dilution in the external medium. HFIAPs caused
fast and extensive release of ANTS from PE/PG (1:1) LUV
(Fig. 1B). In such LUV, the onset of ANTS release took place
at a peptide-to-lipid molar ratios of approximately 1/200 (Fig.
1C). Maximum dye release occurred, however, at about 1/20
peptide/lipid molar ratio, probably when the peptide covers
the whole liposome surface in a carpet-like manner [3]. In
contrast, HFIAPs were much less e¡ective in causing ANTS
release from PC/SM/CHOL (1:1:1) LUV or PC/CHOL (1:1)
LUV. Therefore, both the binding of HFIAPs to LUV mim-
icking biological membranes and also the capacity of HFIAPs
to release vesicle-encapsulated ANTS from those LUV are in
line with their biological activity.
Next, we wished to explore whether the net charge of the
membrane is important for HFIAP-induced permeabilization,
as well as whether the membrane lesion caused by HFIAPs is
sizable. To this aim, LUV containing varying amounts of PC
and PG were loaded with ANTS/DPX, FD-4, or FD-70. As in
the membrane-binding experiments, the higher the amount of
PG, the larger the extent of HFIAP-induced LUV permeabi-
lization (Table 1). In PG-containing LUV, the HFIAP-1-in-
duced permeability pathway allowed similar extents of ANTS
and FD-4 release but a more limited release of FD-70. On the
other hand, the HFIAP-3-induced permeability pathway al-
lowed FD-4 release to a somewhat lesser extent than ANTS,
and did not allow FD-70 release. Because the permeability
pathways induced by HFIAPs in LUV discriminate permeants
according to size, these results imply that under these condi-
tions HFIAPs induce vesicle contents release through a chan-
nel/pore mechanism, without causing the total destruction of
the liposomal membrane. In agreement with this, HFIAPs did
not seem to cause major changes in vesicle structure or mor-
phology, as deduced from dynamic and static light scattering
measurements of LUV before and after peptide treatment
(data not shown).
3.3. Planar lipid bilayer membrane electrophysiology of
HFIAPs
To gain more insight into the mechanism of membrane
permeabilization induced by HFIAPs, electrophysiology of
planar lipid bilayer membranes was used. Addition of
HFIAPs to a solution bathing a planar bilayer led to in-
creased membrane conductance (Fig. 2A). Typically, noise-
like £uctuations were observed, which were characterized by
continuously variable conductance levels (Fig. 2A, top trace).
In addition, a tendency for instability was noted in HFIAP-
treated planar membranes, especially at relatively high trans-
membrane voltages (Fig. 2A, bottom trace).
The results obtained with HFIAPs in planar membranes are
unexpected for ion channels, which typically induce more re-
producible changes in membrane conductance and do not
decrease membrane stability. An alternative explanation is
that membrane lipids are involved in HFIAP pore formation.
Indeed, the behavior observed for HFIAP-treated planar
membranes is reminiscent of membranes modi¢ed by certain
peptides and proteins thought to form lipid-containing pores
rather than purely proteinaceous channels [7,10,15^17]. To
further explore this possibility, a general model for lipidic
pores and lipid bilayer rupture was considered, where pore
enlargement is determined by a balance between membrane
surface tension, decreasing pore energy, and favoring mem-
brane rupture, and membrane line tension, increasing pore
energy, and opposing membrane rupture [18]. By ¢tting the
voltage dependence of membrane lifetime (i.e. the duration of
the membrane until collapse) to a theoretical expression for
lipidic pore enlargement, line tension values can be obtained.
Both HFIAP-1 and HFIAP-3 decreased membrane lifetime at
Fig. 3. In£uence of HFIAPs on lipid transbilayer redistribution.
A: Time course of the transbilayer distribution of pyPC in LUV com-
posed of PE/PG (1:1) (circles), PC/SM/CHOL (1:1:1) (squares), or
PC/CHOL (1:1) (triangles) in the presence of HFIAP-1 (black sym-
bols) or HFIAP-3 (white symbols). LUV were labeled in the outer
lea£et by external addition of pyPC (5 mol% of total lipid) to the
liposome suspension, and the degree of transbilayer redistribution of
pyPC at any given time was estimated from the ratio between exci-
mer and monomer £uorescence intensity signals. Concentrations of
peptide and lipid were 0.5 WM and 25 WM, respectively. At compa-
rable timescales there was no measurable transbilayer movement of
pyPC in the absence of peptides. B: Comparison of the HFIAP-1-
induced pyPC transbilayer redistribution (triangles) and ANTS re-
lease (circles) at di¡erent peptide-to-lipid molar ratios. LUV compo-
sition was PC/PG (1:1) and lipid concentration was 25 WM.
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submicromolar concentrations (Fig. 2B). Moreover, mem-
brane line tension progressively diminished as the amount of
HFIAPs increased, reducing its original value by V35% and
V25% at HFIAP-1 and HFIAP-3 concentrations of 1.0 WM
and 0.78 WM, respectively (Fig. 2C). It is worth emphasizing
here that even small changes in line tension should signi¢-
cantly a¡ect the probability of lipidic pore formation [18].
Thus, these results support the view that HFIAPs form pores
in the membrane together with lipid molecules.
3.4. HFIAP cause lipid transbilayer redistribution
One implication of the lipidic pore concept is that its for-
mation would allow the movement of lipid molecules from
one monolayer of the bilayer to the other. To address this
issue, the £uorescent phosphatidylcholine analog pyPC was
employed. Membrane-incorporated pyPC displays two dis-
tinct peaks in the £uorescence spectrum, one arising from
excited monomeric pyPC molecules and the other arising
from excited dimeric (excimer) pyPC molecules [9]. The trans-
bilayer movement of pyPC can be estimated from the ratio of
the excimer to monomer £uorescence intensity signals. Addi-
tion of HFIAPs to PE/PG (1:1) LUV containing pyPC local-
ized exclusively in the external monolayer led to a rapid trans-
fer of the £uorescent analog to the internal monolayer (Fig.
3A). On the other hand, the transbilayer movement of pyPC
was not increased in PC/SM/CHOL (1:1:1) or PC/CHOL
(1:1) vesicles, paralleling the results obtained in ANTS release
experiments. Moreover, in PG-containing LUV, HFIAPs elic-
ited the transbilayer redistribution of pyPC with similar ki-
netics and at comparable peptide-to-lipid ratios to those ob-
tained in analogous ANTS release experiments (Fig. 3B, and
data not shown). Thus, these results strongly suggest that
HFIAP-caused LUV permeabilization and lipid transbilayer
relocation are mechanistically related phenomena.
3.5. Non-bilayer lipids a¡ect HFIAP-induced membrane
permeabilization
If, as suggested by the results discussed above, HFIAPs
form lipid-containing pores, their membrane-permeabilizing
activities should be sensitive to the lipid composition of the
membrane and, thus, to the physicochemical properties of the
lipid bilayer. In particular, the membrane monolayer must
bend during lipidic pore formation [18]. Lipid monolayers
can be bent in two directions, termed negative and positive
curvature by convention [19], and membrane permeability can
be breached by increasing both types of monolayer curvature
[20]. To assess whether membrane monolayer curvature is
important for HFIAP pore formation, LUV containing cur-
vature-inducing lipids (non-bilayer lipids) were employed.
Non-bilayer lipids having positive intrinsic curvature such as
LPC and LPE generally promoted HFIAP-induced vesicular
ANTS release, whereas non-bilayer lipids having negative in-
trinsic curvature such as DG and OA had the opposite e¡ect
(Fig. 4A). The e¡ect of LPC, LPE, DG, and OA on HFIAP-
induced LUV permeabilization correlated well with their rel-
ative tendency for curvature [21^23]. It is noteworthy that a
number of antimicrobial peptides, exempli¢ed by magainin,
have been shown to form pores displaying a dependence on
curvature similar to that observed with HFIAPs [2,4].
Since the intrinsic curvature of LPC is opposite to that of
DG, further experiments focused on whether LPC and DG
counterbalance each other’s e¡ects on LUV permeabilization.
In agreement with this prediction, HFIAPs induced the re-
lease of ANTS to similar extents in LUV containing both
DG and LPC and in control LUV (Fig. 4A). Since the e¡ects
of non-bilayer lipids on HFIAP-induced LUV permeabiliza-
tion could be due to changes in the peptide a⁄nity for the
membrane, binding studies were also carried out. As shown in
Fig. 4B, however, di¡erences in the capacity of HFIAPs to
bind LUV were not correlated with di¡erences in HFIAP-
induced vesicular ANTS release.
In summary, our investigations reveal that HFIAPs (1)
form relatively large permeability pathways in the membrane
of LUV which allow a size-dependent e¥ux of vesicle-en-
trapped markers, (2) induce continuously variable conduc-
tance changes in planar membranes, with a reduction of pla-
nar membrane lifetime and line tension as expected for lipidic
pores, and (3) cause lipid transbilayer redistribution concom-
itant with vesicular contents release through a mechanism
Fig. 4. E¡ect of non-bilayer lipids on HFIAP-induced LUV permea-
bilization. A: Extents of ANTS release elicited by HFIAP-1 (black
bars) and HFIAP-3 (white bars) in LUV of PC/PG (5/5) (control),
PC/PG/LPC (4/5/1) (LPC), PC/PG/LPE (4/5/1) (LPE), PC/PG/OA
(4/5/1) (OA), PC/PG/DG (4/5/1) (DG), and PC/PG/DG/LPC (2/5/1/
2) (DG+LPC). Peptide and lipid concentrations were 0.25 WM and
25 WM, respectively. Mean valuesS S.E.M. of four independent ex-
periments are shown. B: E¡ect of non-bilayer lipids on the binding
of HFIAPs to LUV. Mean valuesS S.E.M. of three separate experi-
ments are shown. The rest of the conditions are as in A.
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sensitive to changes in membrane monolayer curvature. Thus,
it seems highly plausible that HFIAPs permeabilize mem-
branes by forming pores lined, at least in part, with lipid
molecules. Our ¢ndings of such a membrane-permeabilizing
activity in antimicrobial peptides of a primitive ¢sh adds to
the growing body of evidence suggesting that formation of
lipid-containing pores is a widespread, evolutionarily con-
served mechanism for antimicrobial peptide action [1^4,24].
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